Bispecific Antibody Teclistamab Doubles Survival Odds in Relapsed Multiple Myeloma
Phase III trial shows teclistamab cuts disease progression risk by 71% vs standard chemo in previously treated myeloma patients.
Summary
A major phase III clinical trial called MajesTEC-9 found that teclistamab, a bispecific antibody drug, dramatically outperformed standard chemotherapy combinations in patients with multiple myeloma who had already received one to three prior treatments. At 18 months, nearly 70% of teclistamab patients were progression-free compared to just 27% on standard therapy. Overall survival also improved significantly. The drug works by simultaneously targeting cancer cells and recruiting immune T-cells to destroy them. Published in the New England Journal of Medicine and presented at the American Society of Clinical Oncology 2026 annual meeting, these results could reshape how relapsed myeloma is treated, particularly for patients whose disease has become resistant to current frontline therapies.
Detailed Summary
Multiple myeloma is a blood cancer affecting plasma cells in the bone marrow, and while treatments have improved significantly over the past decade, relapse remains a major challenge. Patients who progress after frontline therapies — which typically include proteasome inhibitors, immunomodulatory drugs, and anti-CD38 antibodies — often have few effective options. This trial directly addresses that unmet need with a novel immunotherapy approach.
The MajesTEC-9 phase III trial enrolled 574 patients with relapsed or refractory multiple myeloma who had received one to three prior lines of therapy. Patients were randomized to receive either teclistamab monotherapy or one of two standard chemotherapy combinations. The results were striking: the 18-month progression-free survival rate was 69.8% with teclistamab versus just 26.9% with standard regimens — a hazard ratio of 0.29, meaning a 71% reduction in the risk of disease progression or death.
Overall survival also improved meaningfully. At 18 months, 79.2% of teclistamab patients were alive compared to 68.6% in the standard therapy group. The overall response rate was 84.5% versus 54.2%, and complete responses were seen in nearly 66% of teclistamab patients compared to only 17% in the control group. These are substantial differences by oncology standards.
Teclistamab is a bispecific antibody that simultaneously binds to BCMA on myeloma cells and CD3 on T-cells, essentially directing the immune system to attack the cancer. This mechanism is significant because it works even in patients whose disease is refractory to both lenalidomide and anti-CD38 therapies — a population with historically poor outcomes.
For the broader longevity and health community, this matters as a demonstration of how next-generation immunotherapies are extending survival in previously treatment-resistant cancers. Caveats include that most trial participants were white and older, and long-term safety data are still maturing.
Key Findings
- 18-month progression-free survival was 69.8% with teclistamab vs 26.9% with standard chemotherapy.
- Overall survival at 18 months improved to 79.2% with teclistamab vs 68.6% with standard therapy.
- Complete response rates were 65.9% with teclistamab versus only 16.8% with standard regimens.
- Drug works by recruiting T-cells to destroy myeloma cells via dual BCMA and CD3 targeting.
- Trial targeted patients refractory to both lenalidomide and anti-CD38 therapy, a high-need group.
Methodology
This is a news report from MedPage Today covering a peer-reviewed phase III randomized controlled trial published in the New England Journal of Medicine and presented at ASCO 2026. The trial enrolled 574 patients across multiple therapy lines, making it a high-quality, adequately powered study with strong evidence basis.
Study Limitations
The article is a news summary and does not report full safety and adverse event data, which are critical for real-world treatment decisions. The patient population was predominantly white and elderly, which may limit generalizability across diverse demographics. Long-term survival outcomes beyond 18 months and quality-of-life data were not covered in this report.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.